Melanotan I (afamelanotide) — from Arizona research lab to FDA-approved for EPP

The researchers asking that question were Mac Hadley and Victor Hruby, a physiologist and a peptide chemist respectively, working with a small team that would spend the better part of two decades refining their answer. What they eventually produced was afamelanotide — the first approved melanocortin peptide drug in history, now known commercially as Scenesse. The path from that lab to regulatory approval took roughly 35 years, passed through multiple clinical development programs, changed hands more than once, and ended not with the cosmetic application originally imagined but with a small, rare disease population for whom the drug was something close to life-changing.

The scientific foundation rested on a simple and well-established observation about human skin biology. When UV radiation hits the skin, keratinocytes release signals — including alpha-MSH, the 13-amino-acid peptide derived from POMC — that bind to MC1R on nearby melanocytes and stimulate the production of eumelanin, the dark brown-black pigment. This is what a tan is, mechanistically: your melanocytes responding to UV stress by producing a pigment that absorbs subsequent UV photons before they can reach DNA. The process takes days because it requires actual synthesis and redistribution of melanin granules within the melanocyte and the surrounding keratinocytes.

The clinical relevance was clear even in 1980. People who tan easily — who have fully functional MC1R alleles and responsive melanocytes — are meaningfully less susceptible to UV-induced DNA damage and subsequent squamous cell and basal cell skin cancers. People who don't tan well, including those with red-hair-color MC1R variants, are at substantially higher risk. Melanoma risk is more complex and doesn't follow the same clean pattern, but the general principle held: melanogenesis is a photoprotective response, and better melanogenesis means better protection. If you could stimulate melanogenesis pharmacologically, before UV exposure rather than in response to it, you might shift the protective equation.

Hadley and Hruby's contribution was not the discovery of alpha-MSH itself — that had been established for decades — but the synthesis of more potent and more stable analogs. Endogenous alpha-MSH has a short half-life in the bloodstream. It is rapidly degraded by proteases, which makes it an ineffective drug candidate on its own. What the Arizona team developed was NDP-alpha-MSH: [Nle4, D-Phe7]-alpha-MSH, a synthetic analog in which two amino acid substitutions make the peptide more resistant to enzymatic degradation and more potent at MC1R. This compound became what was later called Melanotan I. It was, by design, a selective MC1R agonist — powerful enough to produce sustained melanogenesis without requiring repeated daily dosing, and stable enough to achieve therapeutic blood levels.

The early preclinical results were promising. In animal models, NDP-alpha-MSH produced reliable melanogenesis without apparent toxicity. The animals that received it tanned. When the first small human trials began in the 1980s and early 1990s, the results were consistent with the animal data: people who received the compound tanned, including people who would not have tanned meaningfully from UV exposure alone. The effect was described as a tan without the sun, which made for compelling early press but also introduced a complication the researchers had not fully anticipated. The cosmetic appeal of a sunless tanning drug attracted significant commercial interest, which shifted the development narrative in ways that would ultimately make clinical approval harder to achieve.

The cosmetic angle was tempting. Tanning is a multi-billion dollar industry. A peptide that produced a real tan without UV exposure seemed like it could be enormously valuable. But regulatory approval for cosmetic indications requires a different risk-benefit calculation than approval for treating a disease. For a healthy person who wants to tan, the bar for acceptable risk is very low — essentially, the treatment has to be near-perfectly safe, because the baseline condition it addresses is not a disease. Any significant adverse event in a large cosmetic trial changes the calculus immediately. And the compound, while selective for MC1R relative to other melanocortin receptors, was not without side effects. Nausea at higher doses, transient flushing, and stretching or darkening of existing pigmented lesions were all observed. In the context of a cosmetic application, these were difficult to accept.

The development path changed when a research group identified a patient population for whom the drug wasn't a cosmetic convenience but a medical necessity. Erythropoietic protoporphyria, EPP, is a rare genetic metabolic disorder caused by deficiency of the enzyme ferrochelatase. The result is an accumulation of protoporphyrin in red blood cells and plasma. When light — particularly visible light in the blue-violet range, not only UV — hits the skin of an EPP patient, the accumulated protoporphyrin absorbs that light energy and undergoes a photochemical reaction that generates reactive oxygen species inside the skin tissue. The pain this produces is immediate, severe, and unlike sunburn. People with EPP describe burning, stabbing sensations that begin within minutes of sun exposure and can persist for hours to days after. The injury does not always produce visible blistering at first, which is one reason EPP is often misdiagnosed for years — patients present with pain, and doctors see no lesion, and draw the wrong conclusions.

EPP patients learn to avoid light. Not just direct sun. Shade doesn't fully protect them. Window glass doesn't filter the relevant wavelengths. They rearrange their lives around managing phototoxicity: scheduling outdoor activities by season and time of day, covering every surface of exposed skin, carrying medications for after-exposure pain management, sometimes becoming socially isolated from the ordinary world of outdoor activities that most people take for granted. The quality-of-life impact is severe, and until Scenesse there were essentially no effective treatments.

Afamelanotide addresses EPP not by fixing the underlying enzyme deficiency but by building a melanin shield in the skin before light exposure occurs. The mechanism is the same one Hadley and Hruby originally characterized: MC1R stimulation drives sustained eumelanin production in melanocytes, which then gets distributed through the epidermis. This melanin absorbs the blue-violet light that would otherwise reach the accumulated protoporphyrin and trigger the photochemical cascade. It does not cure EPP. But in clinical trials, it meaningfully extended the time EPP patients could spend in daylight without pain — and in a population for whom the ability to go outside for a summer afternoon is not a trivial gain, that matters enormously.

The European Medicines Agency approved afamelanotide (Scenesse) for EPP in 2014, making it the first melanocortin receptor agonist to reach full regulatory approval anywhere in the world. The FDA granted conditional approval — specifically, accelerated approval — in the United States in 2019, also for EPP. The approval came with a requirement for continued post-marketing studies. The delivery system that made the drug clinically practical was developed by the Australian pharmaceutical company Clinuvel: a small bioresorbable implant, roughly the size of a grain of rice, inserted subcutaneously every 60 to 120 days. The implant releases afamelanotide in a slow, sustained curve over weeks, producing the gradual melanogenesis that protects without the peaks and troughs of injectable dosing.

The cosmetic application — the original dream of a tan-without-sun drug — never advanced through formal regulatory development, largely for the risk-benefit reasons described above. What remained was something arguably more significant: proof that a synthetic melanocortin peptide could be safely delivered to human patients, that MC1R stimulation could be sustained over months without catastrophic adverse effects, and that the tanning response it produced was real and functional rather than merely cosmetic. The scientific foundation that Hadley and Hruby laid in Tucson, intended to prevent melanoma in fair-skinned people, ended up protecting a small group of patients from a completely different light-sensitivity condition. The hypothesis — that melanogenesis is photoprotective — turned out to be entirely correct. The disease it eventually treated wasn't the one they were thinking about.

That's often how the path from bench to bedside actually works: not the straight line the original researchers imagined, but something that finds its value in unexpected places. The compound was right. The problem it solved was just different than the one it was designed for.